NCT07108127View on ClinicalTrials.gov

Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

June 20, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

December 31, 2026

Conditions
Rectal CancerHER2-positive
Interventions
DRUG

Trastuzumab biosimilars and pertuzumab biosimilars plus XELOX

Trastuzumab biosimilars and pertuzumab biosimilars combined with oxaliplatin and capecitabine

Trial Locations (1)

100032

RECRUITING

Peking union medical college hospital, Beijing

All Listed Sponsors
lead

Peking Union Medical College Hospital

OTHER

NCT07108127 - Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer | Biotech Hunter | Biotech Hunter